To evaluate the association of baseline stromal TIL levels and delta-TIL with pCR and progression-free survival (PFS) in patients with luminal breast cancer treated with neoadjuvant chemotherapy, highlighting their significance in treatment outcomes.
Key Findings:
Higher baseline TIL levels were associated with improved response to NAC.
Delta-TIL may provide additional prognostic information beyond classical pathological parameters.
The independent prognostic significance of TIL dynamics in HR+/HER2− breast cancer remains controversial, particularly regarding its impact on treatment decisions.
Interpretation:
Dynamic changes in TIL levels during therapy may correlate with treatment response and survival outcomes, suggesting a need for further research in HR+/HER2− breast cancer to inform clinical practice.
Limitations:
The study is retrospective and may be subject to selection bias, potentially affecting the reliability of the findings.
Limited sample size may affect the generalizability of findings to broader populations.
Variability in TIL assessment methods could influence results, complicating comparisons across studies.
Conclusion:
Further investigation is warranted to clarify the relationship between TIL dynamics and clinical outcomes in HR+/HER2− breast cancer, with potential implications for personalized treatment strategies.
